Home > Publications Database > Initiation and modulation of Tau protein phase separation by the drug suramin. > print

001     256516
005     20231004134629.0
024 7 _ |a 10.1038/s41598-023-29846-9
|2 doi
024 7 _ |a pmid:36894559
|2 pmid
024 7 _ |a pmc:PMC9997437
|2 pmc
024 7 _ |a altmetric:143673335
|2 altmetric
037 _ _ |a DZNE-2023-00340
041 _ _ |a English
082 _ _ |a 600
100 1 _ |a Prince, Prabhu Rajaiah
|b 0
245 _ _ |a Initiation and modulation of Tau protein phase separation by the drug suramin.
260 _ _ |a [London]
|c 2023
|b Macmillan Publishers Limited, part of Springer Nature
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1680171248_6409
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
500 _ _ |a CC BY
520 _ _ |a Tau is an intrinsically disordered neuronal protein in the central nervous system. Aggregated Tau is the main component of neurofibrillary tangles observed in Alzheimer's disease. In vitro, Tau aggregation can be triggered by polyanionic co-factors, like RNA or heparin. At different concentration ratios, the same polyanions can induce Tau condensates via liquid-liquid phase separation (LLPS), which over time develop pathological aggregation seeding potential. Data obtained by time resolved Dynamic Light Scattering experiments (trDLS), light and electron microscopy show that intermolecular electrostatic interactions between Tau and the negatively charged drug suramin induce Tau condensation and compete with the interactions driving and stabilizing the formation of Tau:heparin and Tau:RNA coacervates, thus, reducing their potential to induce cellular Tau aggregation. Tau:suramin condensates do not seed Tau aggregation in a HEK cell model for Tau aggregation, even after extended incubation. These observations indicate that electrostatically driven Tau condensation can occur without pathological aggregation when initiated by small anionic molecules. Our results provide a novel avenue for therapeutic intervention of aberrant Tau phase separation, utilizing small anionic compounds.
536 _ _ |a 352 - Disease Mechanisms (POF4-352)
|0 G:(DE-HGF)POF4-352
|c POF4-352
|f POF IV
|x 0
588 _ _ |a Dataset connected to CrossRef, PubMed, , Journals: pub.dzne.de
650 _ 7 |a tau Proteins
|2 NLM Chemicals
650 _ 7 |a Suramin
|0 6032D45BEM
|2 NLM Chemicals
650 _ 7 |a Heparin
|0 9005-49-6
|2 NLM Chemicals
650 _ 7 |a RNA
|0 63231-63-0
|2 NLM Chemicals
650 _ 2 |a Humans
|2 MeSH
650 _ 2 |a tau Proteins: metabolism
|2 MeSH
650 _ 2 |a Suramin: pharmacology
|2 MeSH
650 _ 2 |a Alzheimer Disease: metabolism
|2 MeSH
650 _ 2 |a Heparin
|2 MeSH
650 _ 2 |a RNA: metabolism
|2 MeSH
700 1 _ |a Hochmair, Janine
|0 P:(DE-2719)2812812
|b 1
|e First author
|u dzne
700 1 _ |a Brognaro, Hévila
|b 2
700 1 _ |a Gevorgyan, Susanna
|b 3
700 1 _ |a Franck, Maximilian
|0 P:(DE-2719)9000550
|b 4
|u dzne
700 1 _ |a Schubert, Robin
|b 5
700 1 _ |a Lorenzen, Kristina
|b 6
700 1 _ |a Yazici, Selin
|b 7
700 1 _ |a Mandelkow, Eckhard
|0 P:(DE-2719)2541671
|b 8
|u dzne
700 1 _ |a Wegmann, Susanne
|0 P:(DE-2719)2812695
|b 9
|u dzne
700 1 _ |a Betzel, Christian
|b 10
773 _ _ |a 10.1038/s41598-023-29846-9
|g Vol. 13, no. 1, p. 3963
|0 PERI:(DE-600)2615211-3
|n 1
|p 3963
|t Scientific reports
|v 13
|y 2023
|x 2045-2322
856 4 _ |y OpenAccess
|u https://pub.dzne.de/record/256516/files/DZNE-2023-00340.pdf
856 4 _ |y OpenAccess
|x pdfa
|u https://pub.dzne.de/record/256516/files/DZNE-2023-00340.pdf?subformat=pdfa
909 C O |o oai:pub.dzne.de:256516
|p openaire
|p open_access
|p VDB
|p driver
|p dnbdelivery
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 1
|6 P:(DE-2719)2812812
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 4
|6 P:(DE-2719)9000550
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 8
|6 P:(DE-2719)2541671
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 9
|6 P:(DE-2719)2812695
913 1 _ |a DE-HGF
|b Gesundheit
|l Neurodegenerative Diseases
|1 G:(DE-HGF)POF4-350
|0 G:(DE-HGF)POF4-352
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-300
|4 G:(DE-HGF)POF
|v Disease Mechanisms
|x 0
914 1 _ |y 2023
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0160
|2 StatID
|b Essential Science Indicators
|d 2022-11-09
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1190
|2 StatID
|b Biological Abstracts
|d 2022-11-09
915 _ _ |a WoS
|0 StatID:(DE-HGF)0113
|2 StatID
|b Science Citation Index Expanded
|d 2022-11-09
915 _ _ |a Fees
|0 StatID:(DE-HGF)0700
|2 StatID
|d 2022-11-09
915 _ _ |a OpenAccess
|0 StatID:(DE-HGF)0510
|2 StatID
915 _ _ |a Article Processing Charges
|0 StatID:(DE-HGF)0561
|2 StatID
|d 2022-11-09
915 _ _ |a Creative Commons Attribution CC BY 4.0
|0 LIC:(DE-HGF)CCBY4
|2 HGFVOC
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b SCI REP-UK : 2022
|d 2023-08-24
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2023-08-24
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2023-08-24
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0320
|2 StatID
|b PubMed Central
|d 2023-08-24
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0501
|2 StatID
|b DOAJ Seal
|d 2023-04-12T15:11:06Z
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0500
|2 StatID
|b DOAJ
|d 2023-04-12T15:11:06Z
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b DOAJ : Anonymous peer review
|d 2023-04-12T15:11:06Z
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0600
|2 StatID
|b Ebsco Academic Search
|d 2023-08-24
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b ASC
|d 2023-08-24
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2023-08-24
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1050
|2 StatID
|b BIOSIS Previews
|d 2023-08-24
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2023-08-24
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1040
|2 StatID
|b Zoological Record
|d 2023-08-24
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1150
|2 StatID
|b Current Contents - Physical, Chemical and Earth Sciences
|d 2023-08-24
915 _ _ |a IF < 5
|0 StatID:(DE-HGF)9900
|2 StatID
|d 2023-08-24
920 1 _ |0 I:(DE-2719)1810006
|k AG Wegmann
|l Protein Actions in Neurodegeneration
|x 0
920 1 _ |0 I:(DE-2719)1013014
|k AG Mandelkow 1
|l Structural Principles of Neurodegeneration
|x 1
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a UNRESTRICTED
980 _ _ |a I:(DE-2719)1810006
980 _ _ |a I:(DE-2719)1013014
980 1 _ |a FullTexts

LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21